EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings
Filings indexed
1,019
across all filing types
Latest filing
2026-05-14
Regulatory Filings
Country
US
United States of America
Listing
US
EYPT
EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-14 | English | |
| 8-K - EyePoint, Inc. (0001314102) (Filer) | 2026-05-06 | English | |
| 8-K - EyePoint, Inc. (0001314102) (Filer) | 2026-04-13 | English | |
| 4 - EyePoint, Inc. (0001314102) (Issuer) | 2026-03-24 | English | |
| 8-K - EyePoint, Inc. (0001314102) (Filer) | 2026-03-20 | English | |
| 8-K - EYEPOINT PHARMACEUTICALS, INC. (0001314102) (Filer) | 2026-03-04 | English |
Browse filings by year
19 years- 2026 25 filings
- 2025 70 filings
- 2024 107 filings
- 2023 108 filings
- 2022 52 filings
- 2021 76 filings
- 2020 65 filings
- 2019 74 filings
- 2018 81 filings
- 2017 46 filings
- 2016 39 filings
- 2015 31 filings
- 2014 40 filings
- 2013 32 filings
- 2012 33 filings
- 2011 37 filings
- 2010 32 filings
- 2009 31 filings
- 2008 40 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 45969074 | 8-K | 2026-05-14 | English | ||
| 41807785 | 8-K - EyePoint, Inc. (0001314102) (Filer) | 2026-05-06 | English | ||
| 34434924 | 8-K - EyePoint, Inc. (0001314102) (Filer) | 2026-04-13 | English | ||
| 33034990 | 4 - EyePoint, Inc. (0001314102) (Issuer) | 2026-03-24 | English | ||
| 33002308 | 8-K - EyePoint, Inc. (0001314102) (Filer) | 2026-03-20 | English | ||
| 32889913 | 8-K - EYEPOINT PHARMACEUTICALS, INC. (0001314102) (Filer) | 2026-03-04 | English | ||
| 32889914 | 8-K - EYEPOINT PHARMACEUTICALS, INC. (0001314102) (Filer) | 2026-03-02 | English | ||
| 32889911 | 4 - EYEPOINT PHARMACEUTICALS, INC. (0001314102) (Filer) | 2026-02-18 | English | ||
| 28810273 | SCHEDULE 13G/A Filing | 2026-02-12 | English | ||
| 32889912 | 4 - EYEPOINT PHARMACEUTICALS, INC. (0001314102) (Filer) | 2026-01-07 | English | ||
| 28810484 | 4 Filing | 2026-01-07 | English | ||
| 28810452 | 4 Filing | 2026-01-07 | English | ||
| 28810415 | 8-K Filing | 2026-01-07 | English | ||
| 28810329 | 4 Filing | 2026-01-07 | English | ||
| 28810480 | 4 Filing | 2026-01-06 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
EyePoint Pharmaceuticals, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32254/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32254 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32254 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32254 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32254}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for EyePoint Pharmaceuticals, Inc. (id: 32254)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.